(2S)-2-benzyloxy-3-phenylpropanal | 118535-75-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2S)-2-benzyloxy-3-phenylpropanal
• 英文别名: 2-(benzyloxy)-3-phenylpropanal；(S)-2-(benzyloxy)-3-phenylpropanal；(S)-2-Benzyloxy-3-phenylpropanal；(2S)-3-phenyl-2-phenylmethoxypropanal
• CAS: 118535-75-4
• 化学式: C₁₆H₁₆O₂
• 分子量: 240.302
• InChiKey: GQVSYXPFELPZIK-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (2S)-2-benzyloxy-3-phenylpropanal 在 palladium dihydroxide jones' reagent 、 氢气 、 臭氧 作用下， 以 甲醇 、 乙醚 、 乙醇 、 丙酮 为溶剂， 反应 53.5h， 生成 (S)-5-((S)-1-Hydroxy-2-phenyl-ethyl)-dihydro-furan-2-one
  参考文献：
  名称：

  Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2P3 sites

  摘要：

  Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P-2- P-3 Sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, 1a and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P-2-P-3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P-2 Side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(98)80011-4
• 作为产物：
  描述：

  (S)-2-hydroxy-N-methoxy-N-methyl-3-phenylpropanamide 在 sodium hydride 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 、 正戊烷 为溶剂， 反应 15.58h， 生成 (2S)-2-benzyloxy-3-phenylpropanal
  参考文献：
  名称：

  甲基酮醛醇加成到 α-烷氧基和 α,β-双烷氧基醛的不对称诱导：无环立体控制模型

  摘要：

  描述了在非螯合条件下与 α-烷氧基和 α,β-双烷氧基醛的甲基酮醛醇加成的系统研究。添加到含有单个 α-烷氧基立体中心的醛中通常会提供与用于羰基加成的 Cornforth/极性 Felkin-Anh 模型一致的产物非对映异构体。邻位不对称诱导对醛α-烷基取代基敏感，但对烷氧基保护基团的性质相对不敏感。除了含有额外的 β-烷氧基取代的立体中心的底物之外，醛的 π 面选择性表现出对 α-和 β-立体中心的相对构型的显着依赖性。α-和β-烷氧基取代基呈反关系的醛在大多数情况下表现出良好的非对映选择性，而具有顺式关系的α-和β-烷氧基取代基的醛出乎意料地得到产物混合物。提出了一种基于类似 Cornforth 的过渡态排列的立体化学模型。

  DOI：

  10.1021/ja061010o

文献信息

• Enantioselective synthesis of protected α-hydroxy aldehydes and ketones via hydroxylation of metalated chiral hydrazones
  作者：Dieter Enders、Vidya Bhushan

  DOI：10.1016/s0040-4039(00)87901-0

  日期：1988.1

  α-Benzyloxy aldehydes and α-acetoxy ketones 4 of high enantiomeric purity are prepared in good overall yields via oxaziridine mediated hydroxylation of chiral hydrazone azaenolates. As auxiliaries novel proline derived hydrazine reagents 5 are used.

  高的对映体纯度的α-苄氧基醛和α-乙酰氧基酮4通过恶唑烷介导的手性氮杂酸酯的羟基化反应以良好的总收率制备。作为助剂，使用了新的脯氨酸衍生的肼试剂5。
• A Brønsted Acid Catalyzed Cascade Reaction for the Conversion of Indoles to α‐(3‐Indolyl) Ketones by Using 2‐Benzyloxy Aldehydes
  作者：Ankush Banerjee、Modhu Sudan Maji

  DOI：10.1002/chem.201902268

  日期：2019.9.2

  A Brønsted acid catalyzed, operationally simple, scalable route to several functionalized α-(3-indolyl) ketones has been developed and the long-standing regioisomeric issue has been eliminated by choosing appropriate carbonyls. A readily available and cheap bottle reagent was used as the catalyst. This protocol was also applicable to the synthesis of densely functionalized α-(3-pyrrolyl) ketones. A

  已经开发出布朗斯台德酸催化的，操作简单的，可扩展的途径，以合成多种官能化的α-（3-吲哚基）酮，并且通过选择合适的羰基化合物消除了长期存在的区域异构问题。使用容易获得且便宜的瓶试剂作为催化剂。该方案也适用于高密度官能化的α-（3-吡咯基）酮的合成。详细的机理研究证实烯醇醚作为反应中间体。几种后合成修饰以及易于获得的β-咔啉，色胺，色胺醇和螺吲哚烯碱都证明了这种功能强大的构件的合成效用。基于这一概念，通过级联环化策略构建了功能化的咔唑。
• Diastereoselective Addition of Prochiral Nucleophilic Alkenes to α-Chiral <i>N</i>-Sulfonyl Imines
  作者：David A. Gutierrez、James Fettinger、K. N. Houk、Kaori Ando、Jared T. Shaw

  DOI：10.1021/acs.orglett.1c04219

  日期：2022.2.11

  to chiral α-alkoxy N-tosyl imines is described. Alkene geometry is selectively transferred to the newly formed carbon–carbon bond, resulting in stereochemical control of C1, C2, and C3 of the resulting 2-alkoxy-3-N-tosyl-4-alkyl-5-hexene products. A computational analysis to elucidate the high selectivity is also presented. This methodology was employed in the synthesis of two naturally occurring isomers

  描述了路易斯酸促进前手性E-和Z-烯丙基亲核试剂与手性 α-烷氧基N-甲苯磺酰基亚胺的加成。烯烃几何结构选择性地转移到新形成的碳-碳键上，从而对所得 2-烷氧基-3- N-甲苯磺酰基-4-烷基-5-己烯产物的 C1、C2 和 C3 进行立体化学控制。还提出了阐明高选择性的计算分析。该方法用于合成两种天然存在的硫磺酰胺异构体。
• Total syntheses and configuration assignments of JBIR-04 and unantimycin A
  作者：Yoshinosuke Usuki、Chie Hamada、Tetsuya Satoh

  DOI：10.1039/c7ob01732d

  日期：——

  of JBIR-04 and unantimycin A have been achieved. Comparison of our spectroscopic data with those reported for natural samples verified the structure of the natural products; (2S,4S,6S,7R,9S,28S) configuration was thus assigned via total synthesis.

  已经实现了JBIR-04和unantimycin A的首次全合成。将我们的光谱数据与天然样品报告的光谱数据进行比较，验证了天然产物的结构；因此，通过全合成分配了（2S，4S，6S，7R，9S，28S）配置。
• Renin inhibiting polyhydroxy-monoamides
  申请人：Bio-Mega, Inc.

  公开号：US05354767A1

  公开（公告）日：1994-10-11

  Disclosed herein are compounds of the formula: R.sup.1 CH.sub.2 CH(X)CH(Y)CH(Z)CHR.sup.2 C(O)NHCHR.sup.3 CH(OH)CH(OH)R.sup.4 wherein R.sup.1 is a terminal unit, for example lower cycloalkyl or phenyl; R.sup.2 is, for example, an optionally substituted alkyl, cycloalkylmethyl, benzyl, 4-imidazolylmethyl, 2-thienylmethyl or 4-thiazolylmethyl; R.sup.3 is alkyl, cycloalkylmethyl or an optionally substituted benzyl; R.sup.4 is alkyl or cycloalkyl; and X and Y each is hydroxy and Z is hydrogen, or X and Z each is hydroxy and Y is hydrogen; with the provisos that (a) the carbon atom bearing R.sup.2 has the "R" configuration except when R.sup.2 is 2-thienylmethyl or 2-thiazolylmethyl, X and Y each is hydroxy and Z is hydrogen, then the carbon atom bearing R.sup.2 has the "S" configuration; (b) the carbon atoms bearing R.sup.3 and R.sup.4 each has the "S" configuration; and (c) the carbon atom located between the last-said two carbon atoms has the "R" configuration. The compounds inhibit renin activity and are indicated for the treatment of hypertension and congestive heart failure.

  本文所披露的化合物的公式为：R.sup.1 CH.sub.2 CH(X)CH(Y)CH(Z)CHR.sup.2 C(O)NHCHR.sup.3 CH(OH)CH(OH)R.sup.4，其中R.sup.1是末端单元，例如低环烷基或苯基；R.sup.2是可选的取代基的烷基、环烷基甲基、苄基、4-咪唑甲基、2-噻吩基甲基或4-噻唑基甲基；R.sup.3是烷基、环烷基甲基或可选的取代基的苄基；R.sup.4是烷基或环烷基；X和Y各自是羟基，Z是氢，或者X和Z各自是羟基，Y是氢；但前提是(a)携带R.sup.2的碳原子具有“R”构型，除非R.sup.2是2-噻吩基甲基或2-噻唑基甲基，X和Y各自是羟基，Z是氢，则携带R.sup.2的碳原子具有“S”构型；(b)携带R.sup.3和R.sup.4的碳原子各具有“S”构型；(c)位于上述两个碳原子之间的碳原子具有“R”构型。这些化合物抑制肾素活性，适用于治疗高血压和充血性心力衰竭。